Renaissance Technologies (RenTech)'s ACRV Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 758,440 shares of Acrivon Therapeutics, Inc. (ACRV) worth $1.05 M, representing 0.00% of the portfolio. First purchased in 2024-Q1, this medium-term investment has been held for 9 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in ACRV, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 457,195 shares. Largest reduction occurred in Q2 2024, reducing 48,100 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Acrivon Therapeutics (ACRV) Holding Value Over Time
Track share changes against reported price movement
Quarterly Acrivon Therapeutics (ACRV) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +124,271 | Add 19.60% | 758,440 | $1.39 |
| Q4 2025 | +10,769 | Add 1.73% | 634,169 | $2.41 |
| Q3 2025 | +114,105 | Add 22.40% | 623,400 | $1.81 |
| Q2 2025 | +457,195 | Add 877.53% | 509,295 | $1.19 |
| Q1 2025 | +2,700 | Add 5.47% | 52,100 | $2.03 |
| Q4 2024 | +3,500 | Add 7.63% | 49,400 | $6.02 |
| Q3 2024 | -8,600 | Reduce 15.78% | 45,900 | $7.00 |
| Q2 2024 | -48,100 | Reduce 46.88% | 54,500 | $5.80 |
| Q1 2024 | +102,600 | New Buy | 102,600 | $7.15 |
Renaissance Technologies (RenTech)'s Acrivon Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Acrivon Therapeutics, Inc. (ACRV) in Q1 2024, acquiring 102,600 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Acrivon Therapeutics, Inc. (ACRV) for 9 quarters since Q1 2024.
Renaissance Technologies (RenTech)'s largest addition to Acrivon Therapeutics, Inc. (ACRV) was in Q2 2025, adding 509,295 shares worth $606,061.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 758,440 shares of Acrivon Therapeutics, Inc. (ACRV), valued at approximately $1.05 M.
As of the Q1 2026 filing, Acrivon Therapeutics, Inc. (ACRV) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Acrivon Therapeutics, Inc. (ACRV) was 758,440 shares, as reported at the end of Q1 2026.